secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-06-04T20:06:58+00:00
Accession:  0001193125-26-257390
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx stockholders elect directors, ratify auditor, approve say-on-pay at annual meeting
--------------------------------------------------------------------------------

- Elected George Mclean Milne Jr., Ph.D. (76.9M for, 14.1M withheld) and Paul Fonteyne (86.3M for, 4.8M withheld) as Class II directors.
- Ratified Deloitte & Touche as independent auditor for FY 2026: 102.0M for, 34.5K against, 5.6K abstain.
- Approved non-binding advisory vote on named executive officer compensation: 77.5M for, 13.5M against, 21.1K abstain.
- No other matters were voted on at the June 4, 2026 Annual Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526257390/0001193125-26-257390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526257390/d128401d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer